To MSA patients and carepartners: at CurePSP, we work hard to follow developments by the pharmaceutical companies around the world that are advancing cures and treatments for rare neurodegenerative diseases. We’re reaching out today to let you know that Lundbeck is starting to recruit for a phase II clinical trial to evaluate the clinical safety, tolerability, and efficacy of a potential new treatment for those battling MSA. We encourage you to learn more about this effort. Below, you will find more information on the trial and a link to explore a dedicated website that Lundbeck developed to inform the community about this study”
The AMULET study aims to see if a study drug is safe and effective in slowing the disease progression in people living with multiple system atrophy (MSA).
An individual may qualify for the study if they:
- Are 40 to 75 years of age
- Have been diagnosed with MSA and it has been less than 5 years from the time of onset of MSA symptoms
- Have a knowledgeable and reliable caregiver who will be available throughout the study when caregiver input is needed (approximately every three months)
- Meet additional study criteria
There is no cost to participate in this study. Qualified individuals may receive the study drug free of charge and will not be charged for any study-related procedures. Qualified individuals may also receive the placebo. Any reasonable travel or transportation costs (fuel, bus or railway tickets) will be reimbursed. Food costs will be reimbursed for qualified individuals that travel more than 4 hours to a clinical research study site.
To learn more about the clinical research study and to see if you may qualify, please visit our website at amulet.researchstudytrial.com.